Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D
- A. SzendeAffiliated withCovance Market Access Services Inc. Email author
- , N. K. LeidyAffiliated withUnited Biosource Corporation
- , E. StåhlAffiliated withAstraZeneca R&DUniversity of Aberdeen
- , K. SvenssonAffiliated withHEORConsulting
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The objective of this study was to understand systematic differences in utility values derived from the EQ-5D and the SF-6D in two respiratory populations with heterogeneous disease severity.
This study involved secondary analysis of data from two cross-sectional surveys of patients with asthma (N = 228; Hungary) and COPD (N = 176; Sweden). Disease severity was defined according to GINA and GOLD guidelines for asthma and COPD, respectively. EQ-5D and SF-6D scores and their distributional characteristics were compared across the two samples by disease severity level.
Within each patient population, mean EQ-5D and SF-6D scores were similar for the overall group and for those with moderate disease. Mean scores varied for patients with mild and severe disease. EQ-5D versus SF-6D scores in the asthma group by severity levels were 0.89 versus 0.80, 0.70 versus 0.73, 0.63 versus 0.64, and 0.51 versus 0.63, respectively. EQ-5D versus SF-6D scores in the COPD group by severity levels were 0.85 versus 0.80, 0.73 versus 0.73, 0.74 versus 0.73, and 0.53 versus 0.62, respectively.
Results suggest the EQ-5D and SF-6D do not yield consistent utility values in patients with asthma and COPD due to differences in underlying valuation techniques and the EQ-5D’s limited response options relative to mild disease.
KeywordsAsthma Chronic obstructive pulmonary disease (COPD) EQ-5D Health utilities SF-6D
- Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D
Quality of Life Research
Volume 18, Issue 2 , pp 267-272
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Chronic obstructive pulmonary disease (COPD)
- Health utilities
- Industry Sectors
- Author Affiliations
- 1. Covance Market Access Services Inc., Springfield House, Hyde Street, Leeds, LS2 9LH, UK
- 2. United Biosource Corporation, Bethesda, MD, USA
- 3. AstraZeneca R&D, Lund, Sweden
- 4. University of Aberdeen, Aberdeen, UK
- 5. HEORConsulting, Lund, Sweden